Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
85 hedge funds and large institutions have $426M invested in Adaptimmune Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 33 reducing their positions, and 21 closing their positions.
69% more call options, than puts
Call options by funds: $725K | Put options by funds: $429K
0.19% more ownership
Funds ownership: 11.92% → 12.12% (+0.19%)
8% less funds holding
Funds holding: 92 → 85 (-7)
26% less capital invested
Capital invested by funds: $577M → $426M (-$151M)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
48% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.69M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$4.24M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.23M |
| 4 |
Renaissance Technologies
New York
|
+$1.95M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$620K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.47M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$4.49M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.82M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.81M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WANY
101
Wealthspire Advisors (New York)
New York
| – | -$61K | -11,750 | Closed |
|
|
TI
102
Tidal Investments
Milwaukee,
Wisconsin
| – | -$55K | -10,554 | Closed |
|
|
RE
103
RBC Europe
London,
United Kingdom
| – | -$36.4K | -7,050 | Closed |
|
|
PCM
104
Penserra Capital Management
Orinda,
California
| – | -$16K | -3,135 | Closed |
|
105
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$382 | +84 | New |
|
ADAP Hedge Fund Activity: Q4 2021 in Review
85 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2021, worth a combined $426M — down 26% from $577M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ADAP and 15 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 17 added.
The largest buyer was Morgan Stanley, adding an estimated $8.69M. The largest seller was PFM Health Sciences, cutting an estimated $5.47M.
- 85 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2021, down from 92 in Q3 2021.
- Funds reported $426M of Adaptimmune Therapeutics stock for Q4 2021, down 26% quarter-over-quarter.
- 15 funds opened new Adaptimmune Therapeutics positions in Q4 2021 and 21 closed out, a net change of -6 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2021 was Morgan Stanley, an estimated $8.69M added.
- The largest Adaptimmune Therapeutics seller in Q4 2021 was PFM Health Sciences, an estimated $5.47M sold.
Based on aggregated 13F filings for Q4 2021.